Filtered By:
Therapy: Chemotherapy
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 70189 results found since Jan 2013.
Early T-Cell Precursor Leukemia: A High-Risk Subtype of Acute Lymphoblastic Leukemia, Single Center Experience in Jordan
CONCLUSION: ETP-ALL/LBL represents a high-risk disease subtype of adult ALL. Novel treatment strategies are needed to improve treatment outcomes in this patient's population.PMID:37730482 | DOI:10.1016/j.clml.2023.08.007
Source: Clinical Lymphoma and Myeloma - September 20, 2023 Category: Cancer & Oncology Authors: Khalid Halahleh Isra Muradi Mohammad Zakaria Khalil Lina Halahleh Maher Sughayer Nazmi Kamal Iyad Sultan Kamal Alrabi Source Type: research
Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer
Conclusion: Chemotherapy agents have different effects on the expression of ICP ligands in tumor cells with different pathological types, and this may affect the efficacy of combined immunotherapy. These results provide a theoretical basis for further selection and optimization of the combination of chemotherapy and immunotherapy.PMID:37728201 | DOI:10.1177/15330338231202307
Source: Technology in Cancer Research and Treatment - September 20, 2023 Category: Cancer & Oncology Authors: Yu Zhao Zhe Wang Xiuhuan Shi Ting Liu Wenwen Yu Xiubao Ren Hua Zhao Source Type: research
Pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis
In this study, the efficacy of ATI-2307 was tested in a rabbit model of CM. ATI-2307 demonstrated significant fungicidal activity at dosages between 1 and 2 mg/kg/d, and these results were superior to fluconazole and similar to amphotericin B treatment. When ATI-2307 was combined with fluconazole, the antifungal effect was greater than either therapy alone. While ATI-2307 has potent anticryptococcal activity in the subarachnoid space, its ability to reduce yeasts in the brain parenchyma was relatively less over the same study period. This new drug, with its unique mechanism of fungicidal action and ability to positively in...
Source: Antimicrobial Agents and Chemotherapy - September 20, 2023 Category: Microbiology Authors: Charles D Giamberardino Jennifer L Tenor Dena L Toffaletti Julia R Palmucci Wiley Schell Jane-Valeriane K Boua Choiselle Marius Katharine E Stott Shelby L Steele William Hope Don Cilla John R Perfect Source Type: research
Diethylcarbamazine elicits Ca < sup > 2+ < /sup > signals through TRP-2 channels that are potentiated by emodepside in < em > Brugia malayi < /em > muscles
Antimicrob Agents Chemother. 2023 Sep 20:e0041923. doi: 10.1128/aac.00419-23. Online ahead of print.ABSTRACTFilarial nematode infections are a major health concern in several countries. Lymphatic filariasis is caused by Wuchereria bancrofti and Brugia spp. affecting over 120 million people. Heavy infections can lead to elephantiasis, which has serious effects on individuals' lives. Although current anthelmintics are effective at killing microfilariae in the bloodstream, they have little to no effect against adult parasites found in the lymphatic system. The anthelmintic diethylcarbamazine is one of the central pillars of l...
Source: Antimicrobial Agents and Chemotherapy - September 20, 2023 Category: Microbiology Authors: Paul D E Williams Sudhanva S Kashyap Alan P Robertson Richard J Martin Source Type: research
A US-based national surveillance study for the susceptibility and epidemiology of < em > Clostridioides difficile < /em > isolates with special reference to ridinilazole: 2020-2021
Antimicrob Agents Chemother. 2023 Sep 20:e0034923. doi: 10.1128/aac.00349-23. Online ahead of print.ABSTRACTWe have previously reported on the susceptibility and epidemiology of Clostridioides difficile isolates from six geographically dispersed medical centers in the United States. This current survey was conducted with isolates collected in 2020-2021 from six geographically dispersed medical centers in the United States, with specific attention to susceptibility to ridinilazole as well as nine comparators. C. difficile isolates or stools from patients with C. difficile antibiotic-associated diarrhea were collected and re...
Source: Antimicrobial Agents and Chemotherapy - September 20, 2023 Category: Microbiology Authors: D R Snydman L A McDermott C M Thorpe E J C Goldstein A N Schuetz S Johnson D N Gerding L Gluck D Bourdas K C Carroll C K Lancaster K W Garey Q Wang S T Walk E Duperchy Source Type: research
Characterization of tumor microenvironment and sensitive chemotherapy drugs based on cuproptosis-related signatures in renal cell carcinoma
Aging (Albany NY). 2023 Sep 19;15. doi: 10.18632/aging.205043. Online ahead of print.ABSTRACTCuproptosis is a novel type of copper-induced cell death and is considered as a new therapeutic target for many cancers. Distant metastases occur in about 40% of patients with advanced renal cell carcinoma (RCC), with a poor 5-year prognosis of about 10%. Through a series of comprehensive analyses, four differentially expressed cuproptosis-related lncRNAs (DECRLs) were identified as candidate biomarkers for RCC. The risk model constructed by using these four DECRLs can better predict the prognosis of patients with RCC, which is det...
Source: Aging - September 20, 2023 Category: Biomedical Science Authors: Jiefu Tang Fan Yao Zhiyong Yao Xiao-Liang Xing Source Type: research
Healthcare IT Regulations – What Needs to Be Added and What Needs to Be Removed
There are a lot of rules and regulations in place in the world of healthcare. These are put into place in order to protect patients and organizations. However, the world of healthcare is constantly changing and evolving as we come up with new ideas and solutions. Have the regulations done the same though? Or are there areas that are missing regulations? Or are there areas in healthcare where past regulations are now too restrictive and are holding us back?
In search of answers to these questions, we reached out to our incredibly beautiful Healthcare IT Today Community to see what areas they would add, remove, or update re...
Source: EMR and HIPAA - September 19, 2023 Category: Information Technology Authors: Grayson Miller Tags: Administration Ambulatory C-Suite Leadership Health IT Company Healthcare IT Hospital - Health System LTPAC Regulations 1upHealth 4medica Amanda Heidemann Andrea Mazzoccoli Andrew Norden MD Bill Charnetski Cheryl Cheng Commur Source Type: blogs
Novel Biotin-linked Amphiphilic Calix4arene-based Supramolecular Micelles as Doxorubicin Carriers for Boosted Anticancer Activity
Chem. Commun., 2023, Accepted Manuscript DOI: 10.1039/D3CC04102F, CommunicationDan Du, yudun liu, Jun-Bin Lan, xueli hou, Jiadong Liu, Qinghua Shi, Qing-Wen Huang, Yunsheng Xue, Lin An, Chaoguo Yan The lacking of targeting, and severe toxic and side effects on normal tissues has become an intractable limitations of doxorubicin (DOX)-based chemotherapy. To tackle these drawbacks, supramolecular carrier-mediated chemotherapy is... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - September 19, 2023 Category: Chemistry Authors: Dan Du Source Type: research
Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine
This study aimed to evaluate how chemotherapy changes immune system parameters and whether these changes influence survival outcomes. We sought to identify an easily accessible marker to help choose the appropriate treatment. Patients with PDAC who were suitable for systemic chemotherapy were eligible for the study. Peripheral blood samples were obtained at baseline and after two months of treatment. Lymphocyte subsets were measured using flow cytometry. Correlation with clinical features and survival analyses were performed. In total, 124 patients were enrolled in this study. Seventy patients were treated with mFOLFIRINOX...
Source: International Immunopharmacology - September 19, 2023 Category: Allergy & Immunology Authors: Skaiste Tulyte Dainius Characiejus Reda Matuzeviciene Ausra Janiulioniene Mantas Radzevicius Elena Jasiunaite Tadas Zvirblis Audrius Sileikis Source Type: research
Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair
CONCLUSIONS: In this study, we decipher the molecular processes behind synergistic interactions between chemotherapy and HDAC inhibition. Moreover, we report novel mechanisms to overcome drug resistance in SCLC, which may be relevant to increase the therapeutic success.PMID:37725585 | DOI:10.1158/1078-0432.CCR-23-1795
Source: Cell Research - September 19, 2023 Category: Cytology Authors: Anna Solta Kristiina Boettiger Ildik ó Kovács Christian Lang Zsolt Megyesfalvi Franziska Ferk Miroslav Mi šík Konrad Hoetzenecker Clemens Aigner Christian R Kowol Siegfried Knasmueller Michael Grusch Be áta Szeitz Melinda Rezeli Balazs Dome Karin Sch Source Type: research
RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial
CONCLUSIONS: We report RANK expression to be an independent predictive biomarker for response to NACT in luminal-like breast cancer patients.PMID:37725572 | DOI:10.1158/1078-0432.CCR-23-1801
Source: Cell Research - September 19, 2023 Category: Cytology Authors: Theresa Link Jens-Uwe Blohmer Wolfgang D Schmitt Jan Dominik Kuhlmann Marianne Just Michael Untch Oliver Stotzer Peter A Fasching Marc Thill Mattea Reinisch Andreas Schneeweiss Pauline Wimberger Sabine Seiler Jens Huober Christian Jackisch Kerstin Rhiem C Source Type: research
The Prognostic Significance of P16 Immunohistochemical Expression Pattern in Women with Invasive Ductal Breast Carcinoma
CONCLUSIONS: Our study demonstrated that p16 protein expression increased in ER-positive tumor tissue from patients with invasive ductal breast carcinoma. However, no correlation was found between the p16 protein expression and the other clinicopathological features.PMID:37724141 | PMC:PMC10505467 | DOI:10.52547/rbmb.12.1.83
Source: Mol Biol Cell - September 19, 2023 Category: Molecular Biology Authors: Alireza Rezaei Navidreza Shayan Saman Shirazinia Sara Mollazadeh Negin Ghiyasi-Moghaddam Source Type: research
Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair
CONCLUSIONS: In this study, we decipher the molecular processes behind synergistic interactions between chemotherapy and HDAC inhibition. Moreover, we report novel mechanisms to overcome drug resistance in SCLC, which may be relevant to increase the therapeutic success.PMID:37725585 | DOI:10.1158/1078-0432.CCR-23-1795
Source: Clinical Cancer Research - September 19, 2023 Category: Cancer & Oncology Authors: Anna Solta Kristiina Boettiger Ildik ó Kovács Christian Lang Zsolt Megyesfalvi Franziska Ferk Miroslav Mi šík Konrad Hoetzenecker Clemens Aigner Christian R Kowol Siegfried Knasmueller Michael Grusch Be áta Szeitz Melinda Rezeli Balazs Dome Karin Sch Source Type: research
Ovarian cancer in the older patient: where are we now? What to do next?
Ther Adv Med Oncol. 2023 Sep 16;15:17588359231192397. doi: 10.1177/17588359231192397. eCollection 2023.ABSTRACTIn recent years, major advances have been made toward the individualization of epithelial ovarian cancer care, leading to an overall improvement of patient outcomes. However, real-life data indicate that the oldest populations do not benefit from this, due to aspects related to cancer (more aggressive histopathological features), treatment (i.e. frequently suboptimal), and the host (increased toxicities in patients with lower physiological reserve). A specific risk-benefit perspective should therefore be taken whe...
Source: Adv Data - September 19, 2023 Category: Epidemiology Authors: Fr édérique Rousseau Florence Ranchon Christophe Bardin Naoual Bakrin Vincent Lavou é Leila Bengrine-Lefevre Claire Falandry Source Type: research
Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer: a systematic review and meta-analysis
CONCLUSIONS: First-line immunotherapy plus chemotherapy significantly improved PFS and OS in ES-SCLC patients without liver metastases compared to chemotherapy alone. However, patients with liver metastases did not experience comparable benefits.PMID:37724893 | DOI:10.18632/aging.205035
Source: Aging - September 19, 2023 Category: Biomedical Science Authors: Yan Lin Wei Jiang Cui-Yun Su Xin-Bin Pan Source Type: research
